

Location: Radisson Blu Astrid Hotel, Antwerp, Belgium

Date: November 7th and November 8th, 2019

Moderator: Dr. Arthur Braat – UMC Utrecht

November 7th, 2019

12:00 – 13: 20 Welcome and introduction

Time	Agenda Item	Presenter
1200-1300	Lunch	
1300-1320	Welcome and Introduction Interventional Oncology at Boston Scientific	Dr. Eveline Boucher

13:20 – 14:45 Redefining / repositioning Radioembolization

Time	Agenda Item	Presenter
1320-1340	SIRT's pathway to personalized medicine: from the past to present	Dr. Braat
1340-1410	DosiSphere: Level 1 Evidence Demonstrating the Impact of Personalised Dosimetry in HCC	Prof. Dr. Etienne Garin
1410-1445	Implementing Personalised Dosimetry in HCC – Consensus Recommendations	Prof. Dr. Etienne Garin

14:45 – 15:05

Time	Agenda Item	
1445-1505	Break	

15:05 – 15:45 Clinical Scenarios - Palliative Intent in HCC

Time	Agenda Item	Presenter
1505-1525	Dose and dosimetry related evidence in intermediate and advanced HCC	Prof. Dr. Etienne Garin
1525-1535	Clinical Case: Scenario Palliative Intent without MI	Prof. Dr. Moreno-Reyes
1535-1545	Clinical case: Palliative Intent with MI	TBC

15:45 – 16:40 *Clinical Scenario Curative Intent HCC : Radiation Segmentectomy*

Time	Agenda Item	Presenter
1545-1615	Radiation "surgery or ablation"?: The Clinical Evidence and Key Technical Concepts	TBC
1615-1625	Clinical case: a 41mm HCC	Dr. Alexandre Jadoul
1625-1655	Tumour board clinical case Radiation Segmentectomy	Surgeon – IR – NM – Oncologist - Hepatologist

19:30 – 22:00 *Networking Dinner With Colleagues & Poster Sessions*

Time	Agenda Item	Presenter
1930-2200	Walking Dinner	The Diamond Room

Moderator: Dr. Arthur Braat – UMC Utrecht

November 8th, 2019

08:30 – 09:35 Clinical Scenario Curative Intent HCC : Radiation Lobectomy

Time	Agenda Item	Presenter
0830-0925	The Role of SIRT Prior to Resection + Modified Radiation Lobectomy	Dr. Vouche and Prof. Dr Garin
0925-0935	Clinical Case: 16 cm HCC	Dr. Moelker

09:35 – 10:20 Continuing beyond HCC

Time	Agenda Item	
0935-1000	Optimising Patient Selection for Improved Outcomes in mCRC	Dr. Braat
1000-1010	Clinical case mCRC: From Salvage to Curative Surgery	Dr. Braat

10:10 – 10:30 Take Time to Recharge

Time	Agenda Item	
1010-1030	Break	

10:30 – 11:30 / 13:30 Continuing beyond HCC

Time	Agenda Item	Presenter
1030-1100	Clinical evidence in iCCA - MISPHEC Study Results	Dr. Eveline Boucher
1100-1110	Clinical Case: ICCA 84mm – Complete Response and Bridge to Surgery	Dr. Alexandre Jadoul
1110-1130	Wrap up / Meeting Summary	Dr Jon Bell
1130-1145	Departure/ Switch rooms	
1130-1145	Simplicit ⁹⁰ Y Update	Thibault Mauxion
1145-1330	Practical Case Experience Tips and Tricks	Radial Access in clinical practise for SIRT
		Neil Turner Francois Gurnet
		John Bell

Invited Faculty

<p>Prof. Dr. Étienne Garin, Nuclear Medicine Cancer Center Eugène-Marquis, Rennes, France</p>	<p>Dr. Alexandre Jadoul Nuclear Medicine CHU de Liège, Liège Belgium</p>
<p>Dr. Arthur Braat Nuclear Medicine UMC Utrecht, Utrecht The Netherlands</p>	<p>Prof. Dr. Moreno-Reyes Nuclear Medicine Hôp. Erasme, Brussels Belgium</p>
<p>Dr. Adriaan Moelker Interventional Radiologist Erasmus Medical Center, Rotterdam The Netherlands</p>	<p>Prof. Dr. Christophe Deroose Nuclear Medicine University Hospital euven Belgium</p>
<p>Dr. Jon Bell Interventional Radiologist NHS Manchester, Manchester United Kingdom</p>	<p>Dr. Eveline Boucher Senior Medical Director BTG / Boston Scientific Camberley UK</p>
<p>MDT 1</p>	<p>MDT 3</p>
<p>MDT 2</p>	<p>MDT 4</p>

I

Invited Poster Presenters & Topics (alphabetic order)

<p>Dr. Ahmed Alsultan Research Dr. UMC Utrecht, The Netherlands</p>	<p>Dosimetry In Case of Flow Redistribution</p>
<p>Dr. Laurence Beels Physicist AZ Groeninge Kortrijk Belgium</p>	<p>2013/59/Euratom – How Do We Align in Daily Practice?</p>
<p>Dr. Hendrik Bergsma Radiologist / physicist Erasmus Medical Center, Rotterdam The Netherlands</p>	<p>EMC Rotterdam: A Single Centre Retrospective SIRT Analysis</p>
<p>Ir. Benoît Collette Physicist Hôp. Erasme, Belgium</p>	<p>Liver Function Scintigraphy: My Experience in Simplicity90Y</p>
<p>Dr. Philippe D'Abadie Nuclear Medicine UCL Saint-Luc, Belgium</p>	<p>HCC BCLC A patient high pulmonary shunt to TARE</p>
<p>Dr. Alexandre Jadoul Nuclear Medicine CHU de Liège, Liège Belgium</p>	<p>Comparative Dosimetry Between 99mTC-MAA SPECT-CT and 90Y PET-CT</p>
<p>Dr. Margot Reinders Research Dr/ Promovenda UMC Utrecht The Netherlands</p>	<p>SIRT Delivery Systems: A Description of The Three Commercial Available Systems</p>

Gezien het meertalige karakter van onze regio Benelux is de voertaal 7 & 8 november Engels. Vandaar dat het programma in het Engels ontwikkeld is.

De doelgroep:

- (Interventie) Radiologen
- Nucleaire geneeskundigen
- Klinisch of medisch fysici
- Technisch geneeskundigen
- Verwijzers zoals medisch oncoloog, hepatoloog, MDL arts
- Aanverwante rollen: verpleegkundig specialist, chirurg, apotheker, e.a.

Algemene doel:

Bijdragen aan de verbetering van de behandelresultaten bij de SIRT/ radio-embolisatie behandeling

De inhoudelijke doelen:

- Begrijpen hoe persoonlijke selectieve inwendige radiotherapie (SIRT ook wel radio-embolisatie genoemd) curatieve strategieën kan drijven voor de behandeling van hepatocellulair carcinoom.
- Bespreken, toelichten en uitleggen van recente aanbevelingen van een internationale werkgroep met betrekking tot verschillende onderwerpen (o.a. de patiëntselectie, planning, beeldvorming, behandeling en opvolging na de behandeling) gerelateerd aan de behandeling van HCC met met glassferen voor verschillende klinische scenario's e.g 'radiation segmentectomy, radiation lobectomy, multifocus uni-or bilobar' met en zonder macrovasculaire invasie).
- Leren van level 1 bewijs van de DOSISPEHRE01 studie waar standaard dosimetrie vergeleken wordt met persoonlijke dosimetrie
- Leren hoe SimpliCity90Y software kan bijdragen aan persoonlijke dosimetrie en het ondersteunen van de SIRT community
- Verkrijgen van inzichten in de voortschrijdende bewijzen gerelateerd aan SIRT voor primaire en secundaire lever kanker.

De methode is een interactieve bijeenkomst met vakinhoudelijke specialisten (professoren, artsen fysici MSc en Ir) welke de bijeenkomst drijven met:

- Lezingen, presentaties
- Case studies/ casuïstiek
- 'Ontmoet de expert sessies'
- Poster presentaties
- Interactieve ' hands- on' sessies
- Tumor board discussies

Werkgroep programma:

- External reviewer Prof. Dr. Marnix Lam
- Directeur marketing and brand manager TheraSphere Will van Heerden, Thibault Mauxion
- Medical education, Shelley Hawkins
- Medical and clinical specialists, Jon Bell, Francois Gurnet, Neil Turner
- Team Benelux Sales and Marketing, Zillah Moore, Dries Christiaens, Dagmar Verhaegen, Cinthia Lebrun en Wendy Berkers (contactpersoon t.b.v. accreditatie tel 0031(0) 6 83083704)

Betalingsdetails:

Graag factuur sturen per e-mail aan

Dhr. Dries Christiaens, Manager Benelux

Email: dries.christiaens@btgplc.com

Telefoonnummer 0032 471 182313




Op de factuur graag de vermelding van BTW nummer NL 821 008 390 B01

BIOCOMPATIBLES UK Ltd
Lakeview Riverside Way
Watchmoor Park
Camberley
Surrey GU15 3YL, UK

De volgende aankondiging is de eerste week van augustus verstuurd:

SAVE THE DATE

7-8 NOVEMBER 2019

IMPROVING PATIENT OUTCOMES WITH PERSONALISED SIRT

BTG IO Benelux Meeting | Antwerp, Belgium

BTG Interventional Oncology will be hosting an interactive meeting of lectures, case studies and Q&A sessions run by tumour board experts. This collaborative event aims to improve patient outcomes with SIRT.

Starts 12:00 | Thursday 7 November
Ends 11:15 | Friday 8 November

RADISSON BLU ASTRID HOTEL
Koningin Astridplein 7, ANTWERP B-2018, Belgium
Easy walking distance across Astrid Square from Antwerp Central Station


We look forward to welcoming you at the BTG Benelux Meeting this November in the beautiful city of Antwerp.

OBJECTIVES

- Understand how personalised SIRT can drive curative intent strategies in HCC patients across all BCLC stages
- Discuss recent recommendations on patient selection & treatment planning with TheraSphere™ in HCC clinical scenarios
- Learn about level 1 evidence from DOSISPHERE randomised controlled trial on personalised dosimetry
- Learn how the new SimpliCT^{90Y}™ software supports personalised dosimetry and helps in building a SIRT community
- Gain insights into emerging clinical evidence in primary and secondary liver cancer

PRELIMINARY SCIENTIFIC AGENDA AND REGISTRATION LINK WILL BE AVAILABLE SHORTLY

SimpliCT^{90Y} is a trademark of Biocompatibles UK Ltd. TheraSphere is a trademark of Theragenics, used under license by Biocompatibles UK Ltd. TheraSphere is a registered trademark in China, EU, Japan and Republic of Korea. Biocompatibles UK Ltd is a BTG International group company. BTG and the BTG roundel are registered trademarks of BTG International Ltd.
© 2019 BTG International Ltd. All rights reserved. BE-THS-1900014- EMEA, July 2019. Marcomms

 **BTG Academy**
Medical Education

Gezien het meertalige karakter van onze regio Benelux is de voertaal 7 & 8 november Engels. Vandaar dat de aankondiging in het Engels ontwikkeld is.

BTG IO Benelux Meeting



Veeva Vault n#
Mdeon: 19/V1/11998/110503

BTG IO Benelux Meeting



Veeva Vault n#
Mdeon: 19/V1/11998/110503